Living with the burden of relapse in multiple myeloma from the patient and physician perspective.
Hulin C et al. Leuk Res. 2017 May 31;59:75-84. doi: 10.1016/j.leukres.2017.05.019. [Epub ahead of print].
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
Gregersen H et al. Cancer Med. 2017 Jun 22. doi: 10.1002/cam4.1128. [Epub ahead of print].
Recent advances in understanding multiple myeloma.
Hari P. Hematol Oncol Stem Cell Ther. 2017 Jun 13. pii: S1658-3876(17)30041-9. doi: 10.1016/j.hemonc.2017.05.005. [Epub ahead of print].
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Moreau P et al. Br J Haematol. 2017 May 30. doi: 10.1111/bjh.14780. [Epub ahead of print].
Haematological cancer: Where are we now with the treatment of multiple myeloma?
Morgan GJ et al. Nat Rev Clin Oncol. 2017 Jun 13. doi: 10.1038/nrclinonc.2017.82. [Epub ahead of print].
Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.
Kormann R et al. PLoS One. 2017 Jun 21;12(6):e0179406. doi: 10.1371/journal.pone.0179406. eCollection 2017.
Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?
Ailawadhi S et al. Curr Hematol Malig Rep. 2017 Jun 19. doi: 10.1007/s11899-017-0393-y. [Epub ahead of print].
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications.
Shin J et al. Korean J Intern Med. 2017 Jun 26. doi: 10.3904/kjim.2016.256. [Epub ahead of print].
Drug Discovery and Therapeutic Delivery for the Treatment of B and T cell Tumors.
Stephenson R et al. Adv Drug Deliv Rev. 2017 Jun 15. pii: S0169-409X(17)30094-7. doi: 10.1016/j.addr.2017.06.010. [Epub ahead of print].
Case of multiple myeloma presenting as acute pancreatitis.
Mishra SB et al. Am J Emerg Med. 2017 Jun 6. pii: S0735-6757(17)30448-5. doi: 10.1016/j.ajem.2017.06.009. [Epub ahead of print].
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.
Went M et al. Blood Cancer J. 2017 Jun 16;7(6):e573. doi: 10.1038/bcj.2017.48.
Melflufen – a peptidase-potentiated alkylating agent in clinical trials.
Wickström M et al. Oncotarget. 2017 Jun 8. doi: 10.18632/oncotarget.18420. [Epub ahead of print].
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
Podar K et al. Expert Opin Pharmacother. 2017 Jun 12. doi: 10.1080/14656566.2017.1340942. [Epub ahead of print].
Kidney Function, Proteinuria, and Cancer Incidence: The Korean Heart Study.
Mok Y et al. Am J Kidney Dis. 2017 Jun 7. pii: S0272-6386(17)30636-4. doi: 10.1053/j.ajkd.2017.03.018. [Epub ahead of print].
Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades.
Sun T et al. Leuk Lymphoma. 2017 Jun 9:1-10. doi: 10.1080/10428194.2017.1335398. [Epub ahead of print].
Coexistence of chronic lymphocytic leukemia and multiple myeloma, do the roots of these entities originate from the same place?
Merdin A et al. Clin Case Rep. 2017 Apr 12;5(6):1032-1033. doi: 10.1002/ccr3.951. eCollection 2017 Jun.
Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
Milone G et al. Leuk Lymphoma. 2017 Jun 2:1-7. doi: 10.1080/10428194.2017.1324161. [Epub ahead of print].
Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model.
Martino M et al. Clin Lymphoma Myeloma Leuk. 2017 Jun 6. pii: S2152-2650(16)30736-4. doi: 10.1016/j.clml.2017.05.018. [Epub ahead of print].
Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.
Sharkey MM et al. Int J Clin Pharm. 2017 Jun 1. doi: 10.1007/s11096-017-0480-0. [Epub ahead of print].
A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma.
Mercurio A et al. Curr Med Chem. 2017 May 31. doi: 10.2174/0929867324666170601074646. [Epub ahead of print].